Outcomes and Therapeutic Management of Bladder Cancer

Outcomes and Therapeutic Management of Bladder Cancer

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invas...

Full description

Saved in:
Bibliographic Details
Sonstige:
Moschini, Marco
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (120 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545859804498
ctrlnum (CKB)5400000000040901
(oapen)https://directory.doabooks.org/handle/20.500.12854/69079
(EXLCZ)995400000000040901
collection bib_alma
record_format marc
spelling Moschini, Marco edt
Outcomes and Therapeutic Management of Bladder Cancer
Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
1 electronic resource (120 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.
English
Medicine bicssc
bladder cancer
robotic-assisted
open
radical cystectomy
survival
propensity score
age
urothelial carcinoma
outcome
anesthesia recovery periods
cognitive impairment
gamma-cyclodextrins
neuromuscular blockade
robotic radical cystectomy
glycogen
clear-cell adenocarcinoma
urinary bladder
SEER program database
female
intracorporeal neobladder
outcomes
robotic
sex-sparing
methylation
biomarkers
FOXA1
GATA3
KRT20
molecular markers
mRNA
muscle-invasive bladder cancer
PCR
human epidermal growth factor receptor 2
indoleamine 2,3-dioxygenase
programmed death ligand-1
immunotherapy
nodal disease
pN1
neoadjuvant
adjuvant
chemotherapy
3-03936-934-2
3-03936-935-0
Moschini, Marco oth
language English
format eBook
author2 Moschini, Marco
author_facet Moschini, Marco
author2_variant m m mm
author2_role Sonstige
title Outcomes and Therapeutic Management of Bladder Cancer
spellingShingle Outcomes and Therapeutic Management of Bladder Cancer
title_full Outcomes and Therapeutic Management of Bladder Cancer
title_fullStr Outcomes and Therapeutic Management of Bladder Cancer
title_full_unstemmed Outcomes and Therapeutic Management of Bladder Cancer
title_auth Outcomes and Therapeutic Management of Bladder Cancer
title_new Outcomes and Therapeutic Management of Bladder Cancer
title_sort outcomes and therapeutic management of bladder cancer
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2020
physical 1 electronic resource (120 p.)
isbn 3-03936-934-2
3-03936-935-0
illustrated Not Illustrated
work_keys_str_mv AT moschinimarco outcomesandtherapeuticmanagementofbladdercancer
status_str n
ids_txt_mv (CKB)5400000000040901
(oapen)https://directory.doabooks.org/handle/20.500.12854/69079
(EXLCZ)995400000000040901
carrierType_str_mv cr
is_hierarchy_title Outcomes and Therapeutic Management of Bladder Cancer
author2_original_writing_str_mv noLinkedField
_version_ 1787548726643916800
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02757nam-a2200781z--4500</leader><controlfield tag="001">993545859804498</controlfield><controlfield tag="005">20231214133626.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000040901</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69079</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000040901</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Moschini, Marco</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcomes and Therapeutic Management of Bladder Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (120 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">robotic-assisted</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">open</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radical cystectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">propensity score</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">age</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urothelial carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">outcome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anesthesia recovery periods</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cognitive impairment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gamma-cyclodextrins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neuromuscular blockade</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">robotic radical cystectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycogen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clear-cell adenocarcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urinary bladder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SEER program database</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">female</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intracorporeal neobladder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">outcomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">robotic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sex-sparing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">methylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FOXA1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">GATA3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">KRT20</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular markers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">muscle-invasive bladder cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PCR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human epidermal growth factor receptor 2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">indoleamine 2,3-dioxygenase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">programmed death ligand-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nodal disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pN1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neoadjuvant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adjuvant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-934-2</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-935-0</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moschini, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:59:44 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338070490004498&amp;Force_direct=true</subfield><subfield code="Z">5338070490004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338070490004498</subfield></datafield></record></collection>

Similar Items